JNJ

186.02

-0.73%↓

ABT

125.16

-1.27%↓

ISRG

539.84

-0.58%↓

DHR

218.01

-0.1%↓

BSX

100.44

-0.86%↓

JNJ

186.02

-0.73%↓

ABT

125.16

-1.27%↓

ISRG

539.84

-0.58%↓

DHR

218.01

-0.1%↓

BSX

100.44

-0.86%↓

JNJ

186.02

-0.73%↓

ABT

125.16

-1.27%↓

ISRG

539.84

-0.58%↓

DHR

218.01

-0.1%↓

BSX

100.44

-0.86%↓

JNJ

186.02

-0.73%↓

ABT

125.16

-1.27%↓

ISRG

539.84

-0.58%↓

DHR

218.01

-0.1%↓

BSX

100.44

-0.86%↓

JNJ

186.02

-0.73%↓

ABT

125.16

-1.27%↓

ISRG

539.84

-0.58%↓

DHR

218.01

-0.1%↓

BSX

100.44

-0.86%↓

Search

Thermo Fisher Scientific Inc

Отворен

СекторЗдравеопазване

565.75 1.65

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

553.91

Максимум

571.44

Ключови измерители

By Trading Economics

Приходи

100M

1.6B

Продажби

491M

11B

P/E

Средно за сектора

31.148

37.461

Дивидентна доходност

0.3

Марж на печалбата

14.878

Служители

125,000

EBITDA

1.1B

2.8B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+10.37% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.30%

2.33%

Следваща дата на екс-дивидент

12.12.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

52B

205B

Предишно отваряне

564.1

Предишно затваряне

565.75

Настроения в новините

By Acuity

29%

71%

74 / 373 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Thermo Fisher Scientific Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.10.2025 г., 20:49 ч. UTC

Печалби

Correction to Thermo Fisher Article on Oct. 22

22.10.2025 г., 10:28 ч. UTC

Печалби

Thermo Fisher 3Q Revenue Rises, Boosted by Life Sciences Business

23.07.2025 г., 10:33 ч. UTC

Печалби

Thermo Fisher Scientific 2Q Profit, Revenue Rise

25.06.2025 г., 21:19 ч. UTC

Придобивния, сливания и поглъщания

Solventum Removes Drinking-Water Unit From Thermo Fisher's Planned Filtration Buy

28.05.2025 г., 14:02 ч. UTC

Придобивния, сливания и поглъщания

Brookfield, Caisse de Depot Buy Antylia Scientific From GTCR for $1.34 Billion

23.04.2025 г., 10:33 ч. UTC

Печалби

Thermo Fisher 1Q Net, Revenue Up, Costs Stable

22.10.2025 г., 10:01 ч. UTC

Печалби

Thermo Fisher 3Q Organic Revenue Rose 3% >TMO

22.10.2025 г., 10:00 ч. UTC

Печалби

Thermo Fisher: In Great Position to Deliver on 2025 Objectives >TMO

22.10.2025 г., 10:00 ч. UTC

Печалби

Thermo Fisher 3Q Adj EPS $5.79 >TMO

22.10.2025 г., 10:00 ч. UTC

Печалби

Thermo Fisher 3Q Rev $11.12B >TMO

22.10.2025 г., 10:00 ч. UTC

Печалби

Thermo Fisher 3Q Net $1.62B >TMO

22.10.2025 г., 10:00 ч. UTC

Печалби

Thermo Fisher 3Q EPS $4.27 >TMO

2.09.2025 г., 12:15 ч. UTC

Придобивния, сливания и поглъщания

Thermo Fisher Scientific Completes Acquisition Of Sanofi's Ridgefield, New Jersey Site >TMO

2.09.2025 г., 12:08 ч. UTC

Придобивния, сливания и поглъщания

Solventum Had Seen 2025 Adjusted EPS $5.80-$5.95 >SOLV

2.09.2025 г., 12:08 ч. UTC

Придобивния, сливания и поглъщания

Solventum Raises 2025 View To Adj EPS $5.88-Adj EPS $6.03 >SOLV

2.09.2025 г., 12:04 ч. UTC

Придобивния, сливания и поглъщания

Solventum to Use Net Proceeds Primarily to Pay Down Debt >SOLV

2.09.2025 г., 12:03 ч. UTC

Придобивния, сливания и поглъщания

Solventum Closes Sale of Unit to Thermo Fisher for $4 Billion in Cash >SOLV

2.09.2025 г., 12:03 ч. UTC

Придобивния, сливания и поглъщания

Thermo Fisher Completes Acquisition of Purification & Filtration Business of Solventum for About $4B in Cash >TMO

2.09.2025 г., 12:00 ч. UTC

Придобивния, сливания и поглъщания

Solventum Completes Sale of Purification & Filtration Business to Thermo Fisher Scientific >SOLV TMO

23.07.2025 г., 10:00 ч. UTC

Печалби

Thermo Fisher 2Q Organic Revenue Rose 2% >TMO

23.07.2025 г., 10:00 ч. UTC

Печалби

Thermo Fisher 2Q Adj EPS $5.36 >TMO

23.07.2025 г., 10:00 ч. UTC

Печалби

Thermo Fisher 2Q Net $1.62B >TMO

23.07.2025 г., 10:00 ч. UTC

Печалби

Thermo Fisher 2Q EPS $4.28 >TMO

23.07.2025 г., 10:00 ч. UTC

Печалби

Thermo Fisher 2Q Rev $10.85B >TMO

14.07.2025 г., 16:12 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

14.07.2025 г., 15:06 ч. UTC

Придобивния, сливания и поглъщания

Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit -- Barrons.com

28.05.2025 г., 13:47 ч. UTC

Придобивния, сливания и поглъщания

Brookfield, Caisse de Depot Buy Antylia Scientific From GTCR for $1.34B

23.04.2025 г., 10:01 ч. UTC

Печалби

Thermo Fisher 1Q Adjusted Operating Margin 21.9% >TMO

23.04.2025 г., 10:00 ч. UTC

Печалби

Thermo Fisher 1Q Organic Revenue Rose 1% >TMO

23.04.2025 г., 10:00 ч. UTC

Печалби

Thermo Fisher 1Q EPS $3.98 >TMO

Сравнение с други в отрасъла

Ценова промяна

Thermo Fisher Scientific Inc Прогноза

Ценова цел

By TipRanks

10.37% нагоре

12-месечна прогноза

Среден 615.44 USD  10.37%

Висок 675 USD

Нисък 561 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Thermo Fisher Scientific Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

20 ratings

17

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

406.5 / 417.79Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Strong Bearish Evidence

Настроение

By Acuity

74 / 373 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar
help-icon Live chat